{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:37:33Z","timestamp":1777934253635,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T00:00:00Z","timestamp":1468022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>Enzalutamide is an androgen receptor antagonist used for the treatment of metastatic castration-resistant prostate cancer. Enzalutamide is classified as a strong cytochrome P450 3A4 inducer, a moderate 2C9 and 2C19 inducer, and a time-dependent inducer of 1A2. Warfarin\u2019s more potent enantiomer is primarily metabolized by cytochrome P450 2C9 and has a narrow therapeutic window. Enzalutamide is thought to decrease therapeutic warfarin concentrations per pharmacokinetic studies performed during drug development. This case report describes a 59\u2013year-old man undergoing treatment with enzalutamide for metastatic castration-resistant prostate cancer with a history of femoral vein thrombosis. The patient was receiving a total weekly warfarin dose of 37.5\u2009mg prior to starting enzalutamide. Enzalutamide was initiated and warfarin continued at a constant dose without decrease in the patient\u2019s INR. The patient continued on enzalutamide and warfarin for 1 year without having any documented subtherapeutic INRs. This report illustrates one case in which the interaction between warfarin and enzalutamide was not clinically significant.<\/jats:p>","DOI":"10.1177\/1078155215609979","type":"journal-article","created":{"date-parts":[[2015,10,10]],"date-time":"2015-10-10T21:17:45Z","timestamp":1444511865000},"page":"68-70","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Lack of interaction between enzalutamide and warfarin in a metastatic castration-resistant prostate cancer patient"],"prefix":"10.1177","volume":"23","author":[{"given":"Elizabeth A","family":"Casserly","sequence":"first","affiliation":[{"name":"Central Arkansas Veterans Health System, Pharmacy Department, Little Rock, Arkansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara E","family":"Rogers","sequence":"additional","affiliation":[{"name":"Central Arkansas Veterans Health System, Pharmacy Department, Little Rock, Arkansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney V","family":"Keisner","sequence":"additional","affiliation":[{"name":"Central Arkansas Veterans Health System, Pharmacy Department, Little Rock, Arkansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,7,9]]},"reference":[{"key":"bibr1-1078155215609979","unstructured":"Astellas Pharma US, Inc. Xtandi (enzalutamide) (package insert). Northbrook, IL, Astellas Pharma US, Inc, 2014."},{"key":"bibr2-1078155215609979","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"bibr3-1078155215609979","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"bibr4-1078155215609979","first-page":"235","volume":"7","author":"El-Amm J","year":"2013","journal-title":"Clin Med Insight Oncol"},{"key":"bibr5-1078155215609979","first-page":"11449","volume":"27","author":"Hurwitz M","year":"2013","journal-title":"Oncology"},{"key":"bibr6-1078155215609979","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0283-1"},{"key":"bibr7-1078155215609979","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(07)80081-6"},{"key":"bibr8-1078155215609979","doi-asserted-by":"publisher","DOI":"10.1016\/S1072-7515(01)01163-2"},{"key":"bibr9-1078155215609979","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-010-0535-8"},{"key":"bibr10-1078155215609979","unstructured":"Roxane Laboratories, Inc. Coumadin (warfarin) (package insert). Columbus, Ohio: Roxane Laboratories, Inc., 2012."},{"key":"bibr11-1078155215609979","doi-asserted-by":"publisher","DOI":"10.2174\/1872312811206030002"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215609979","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155215609979","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215609979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:28Z","timestamp":1777688188000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155215609979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,9]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1177\/1078155215609979"],"URL":"https:\/\/doi.org\/10.1177\/1078155215609979","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,9]]}}}